Newron Pharmaceuticals S.p.A. (FRA:NP5)
Germany flag Germany · Delayed Price · Currency is EUR
11.26
+0.06 (0.54%)
At close: Sep 26, 2025

Newron Pharmaceuticals Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
23118695282835
Upgrade
Market Cap Growth
41.50%95.60%239.07%0.38%-21.34%-66.00%
Upgrade
Enterprise Value
240223126443322
Upgrade
Last Close Price
11.329.295.601.471.501.91
Upgrade
PE Ratio
9.1111.72----
Upgrade
PS Ratio
3.863.6110.484.594.846.74
Upgrade
PB Ratio
145.93127.32-3.17-1.998.982.06
Upgrade
P/TBV Ratio
146.02127.32--8.982.06
Upgrade
EV/Sales Ratio
4.024.3413.957.265.774.13
Upgrade
EV/EBITDA Ratio
6.808.52----
Upgrade
EV/EBIT Ratio
6.848.53----
Upgrade
Debt / Equity Ratio
33.2334.62-1.62-3.2513.871.53
Upgrade
Debt / EBITDA Ratio
1.491.91----
Upgrade
Asset Turnover
1.391.150.290.140.110.09
Upgrade
Quick Ratio
1.402.420.625.5010.585.50
Upgrade
Current Ratio
1.512.600.685.6510.795.50
Upgrade
Return on Equity (ROE)
-----146.43%-77.71%
Upgrade
Return on Assets (ROA)
50.97%36.44%-23.05%-18.96%-15.19%-20.26%
Upgrade
Return on Capital (ROIC)
60.97%46.45%-28.99%-21.37%-17.21%-23.21%
Upgrade
Return on Capital Employed (ROCE)
165.20%64.80%----
Upgrade
Earnings Yield
10.97%8.54%-17.09%-62.50%-53.44%-59.23%
Upgrade
FCF Yield
10.63%-9.50%-10.70%-39.69%-41.12%-44.07%
Upgrade
Buyback Yield / Dilution
-16.86%-15.30%----
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.